Z Gastroenterol 2014; 52(12): 1495-1499
© Georg Thieme Verlag KG Stuttgart · New York
Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Simeprevir-Nutzenbewertung gemäß § 35a SGB V des G-BA
Literaturverzeichnis
1 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562
2 Poethko-Muller C, Zimmermann R, Hamouda O et al. Epidemiology of hepatitis A, B, and C among adults in Germany. Results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2013; 56: 707-715
3 Wiegand J, Petroff D, Bätz O et al. Identification of HBV and HCV infections in the primary care setting: pre-defined risk scenarios are a better screening strategy than elevated ALT values. Journal of Hepatology 2014; 60 (Suppl. 01) S513
4 Vermehren J, Schlosser B, Domke D et al. High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. PLoS One 2012; 7: e41206
5 Razavi H, Waked I, Sarrazin C et al. The present and future disease burden of hepatitis C virus (HCV) infection with today‘s treatment paradigm. J Viral Hepat 2014; 21 (Suppl. 01) 34-59
6 Ly KN, Xing J, Klevens RM et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278
7 Potthoff A, Brockmeyer N, Kompetenznetz HA. [HIV infection 2007]. Med Klin (Munich) 2007; 102: 531-539
8 Wedemeyer H, Duberg AS, Buti M et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21 (Suppl. 01) 60-89
9 Sarrazin C, Berg T, Ross RS et al. Update der S3-Leitlinie Prophylaxe, Diagnose und Therapie der Hepatitis C Virus (HCV) Infektion. Z Gastroenterol 2010; 48: 289-351
10 Niederau C, Huppe D, Zehnter E et al. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World J Gastroenterol 2012; 18: 1339-1347
11 Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011; 364: 2405-2416
12 Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011; 364: 2417-2428
13 Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217
14 Poordad F, McCone Jr J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206
15 Sarrazin C, Berg T, Cornberg M et al. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Z Gastroenterol 2012; 50: 57-72
16 Werner CR, Franz C, Egetemeyr DP et al. Efficacy and safety of telaprevir (TVR) triple therapy in a ‚real-life‘ cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. J Viral Hepat 2014; 21: 333-340
17 Hezode C, Fontaine H, Dorival C et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142 e134
18 Sofia MJ, Bao D, Chang W et al. Discovery of a beta-d-2‘-deoxy-2‘-alpha-fluoro-2‘-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53: 7202-7218
19 Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887
20 Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877
21 Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir plus ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the Valence trial. Hepatology 2013; 58: 1085A
22 Sarrazin C, Berg T, Buggisch P et al. Aktuelle Empfehlung der DGVS und des bng zur Therapie der chronischen Hepatitis C. Z Gastroenterol 2014; 52: 749-757
23 Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;
24 Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221
25 Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493
26 Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898
27 Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888
28 Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603
29 Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614
30 Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982
31 Ferenci P, Bernstein D, Lalezari J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-1992
32 Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;
33 Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;
34 Forns X, Lawitz E, Zeuzem S et al. Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. Gastroenterology 2014;
35 Reddy K, Zeuzem S, Zoulim F et al. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study.. Hepatol Int 2014; 8: S397
36 Moreno C, Hezode C, Marcellin P et al. Once-daily simeprevir (TMC435) with peginterferon / ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial. Journal of Hepatology 2014; 60: S535-S535
37 Yee BE, Nguyen NH, Zhang B et al. Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin. Eur J Gastroenterol Hepatol 2014;
38 Mauss S, Berger F, Vogel M et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012; 50: 441-444
39 Poynard T, Colombo M, Bruix J et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa / ribavirin therapy. Gastroenterology 2009; 136: 1618-1628 e1612
40 Buggisch P, Zeuzem S, Teuber G et al. Treating Relapse with Peginterferon Alfa-2a Plus Ribavirin and Amantadin for Either 72 or 48 Weeks (in Patients with Hcv-Type 1/3 Infection): Results from the Trela-Study. Journal of Hepatology 2009; 50: S382-S382
41 Vierling JM, Zeuzem S, Poordad F et al. Safety and efficacy of boceprevir / peginterferon / ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol 2014; 61: 200-209
42 Jensen DM, Marcellin P, Freilich B et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-540
43 Flamm SL, Lawitz E, Jacobson I et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013; 11: 81-87 e84; quiz e85.
44 van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593
45 Wiese M, Fischer J, Lobermann M et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 2014; 59: 49-57
46 Fransen van de Putte DE, Makris M, Fischer K et al. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol 2014; 60: 39-45
47 Arase Y, Kobayashi M, Suzuki F et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57: 964-973
